Diffuse Spontaneous Laryngeal Hemorrhage with Trastuzumab
- PMID: 32908757
- PMCID: PMC7463383
- DOI: 10.1155/2020/8818905
Diffuse Spontaneous Laryngeal Hemorrhage with Trastuzumab
Abstract
Drug-induced epithelial hemorrhage of the endolarynx is an unusual etiology of hemoptysis. We present a case of hemoptysis in a young female patient undergoing treatment for metastatic breast cancer with trastuzumab emtansine. Though previously associated with diffuse spontaneous hemorrhage of the gingiva, there have not been reports of laryngeal hemorrhage with trastuzumab emtansine treatment. In this case report, we suggest that trastuzumab emtansine played a contributory role in the development of diffuse epithelial laryngeal hemorrhage and describe the pathophysiology, history, laryngoscopic findings, and management of this condition.
Copyright © 2020 Lauren Klute et al.
Conflict of interest statement
The authors declare that they have no conflicts of interest regarding the publication of this article.
Figures
References
-
- Earwood J. S., Thompson T. D. Hemoptysis: evaluation and management. American Family Physician. 2015;91(4):243–249. - PubMed
-
- Rhodes J. E. Hemorrhage of the larynx. JAMA: The Journal of the American Medical Association. 1904;XLIII(18):1284–1289. doi: 10.1001/jama.1904.92500180001d. - DOI
-
- Verma S., Miles D., Gianni L., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. 2012. https://www.ncbi.nlm.nih.gov/pubmed/23020162. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
